A growing medtech role in NHS copayment reforms?
This article was originally published in Clinica
UK plans unveiled yesterday to expand access to NHS treatments and to allow private treatment to run in parallel to NHS care, enabling patients to have an active role in embracing innovative – and potentially more costly – treatments, should increasingly impinge on access to innovative medical technology too. So suggests the UK-based pan-regional lobby association, the Medical Technology Group (MTG), in recommendations submitted to the House of Commons health select committee (HSC), as part of an inquiry into patient safety*.
You may also be interested in...
Switzerland’s SIX exchange-listed drug development company, Basilea, is moving two new oncology candidates along its R&D pipeline, supported by strong revenues from two partnered anti-infective products.
Recommendations from the Alliance for Regenerative Medicine aim to improve cross-border healthcare to ensure patients can access advanced therapies.
At the OurCrowd Global Investor Summit in Jerusalem, Israel, on 13 February, Medtech Insight met wound care device company Nanomedic to find out more about its unique electro-spinning technology.